Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a small update to the study record metadata on ClinicalTrials.gov.
    Difference
    0.0%
    Check dated 2026-05-18T03:59:15.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    Taoyuan District, Taiwan, 333 was replaced with Taoyuan, Taiwan, 333 in the Locations section to standardize the city designation for the study site.
    Difference
    0.0%
    Check dated 2026-05-03T17:41:50.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Updated the page’s footer revision/version indicator from v3.5.2 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-26T15:21:29.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    Location entries were updated to list Viña del Mar as Viña del Mar, Valparaiso, Chile (postal code 2520598) and Valparaiso as a separate location, and Ono Pharmaceutical Co., Ltd. was added as a collaborator; the revision version updated from v3.5.0 to v3.5.2.
    Difference
    0.3%
    Check dated 2026-04-19T13:38:50.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    Padua, Italy, 35128 was updated to Padova, Italy, 35128 in the locations list.
    Difference
    0.0%
    Check dated 2026-04-05T06:22:23.000Z thumbnail image
  9. Check
    73 days ago
    Change Detected
    Summary
    Napoli, Italy, 80131 was updated to Naples, Italy, 80131 in the locations listing, a Genetic and Rare Diseases Information Center resource was added, the Hepatocellular carcinoma term was added, and the revision version changed from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-21T17:19:18.000Z thumbnail image

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.